BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 35806472)

  • 21. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
    Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR
    Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Canadian Multicentric Pan-TRK (CANTRK) Immunohistochemistry Harmonization Study.
    Hyrcza MD; Martins-Filho SN; Spatz A; Wang HJ; Purgina BM; Desmeules P; Park PC; Bigras G; Jung S; Cutz JC; Xu Z; Berman DM; Sheffield BS; Cheung CC; Leduc C; Hwang DM; Ionescu D; Klonowski P; Chevarie-Davis M; Chami R; Lo B; Stockley TL; Tsao MS; Torlakovic E
    Mod Pathol; 2024 Jan; 37(1):100384. PubMed ID: 37972928
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population.
    Zhao R; Yao F; Xiang C; Zhao J; Shang Z; Guo L; Ding W; Ma S; Yu A; Shao J; Zhu L; Han Y
    J Pathol Clin Res; 2021 Jul; 7(4):375-384. PubMed ID: 33768710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.
    Chou A; Fraser T; Ahadi M; Fuchs T; Sioson L; Clarkson A; Sheen A; Singh N; Corless CL; Gill AJ
    Mod Pathol; 2020 May; 33(5):924-932. PubMed ID: 31792356
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).
    Chu YH; Dias-Santagata D; Farahani AA; Boyraz B; Faquin WC; Nosé V; Sadow PM
    Mod Pathol; 2020 Nov; 33(11):2186-2197. PubMed ID: 32457407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
    Xu B; Haroon Al Rasheed MR; Antonescu CR; Alex D; Frosina D; Ghossein R; Jungbluth AA; Katabi N
    Histopathology; 2020 Feb; 76(3):375-382. PubMed ID: 31448442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
    Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
    Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How Sensitive is Pan-TRK Immunohistochemistry for Detecting NTRK Fusions in Papillary Thyroid Carcinoma?
    Hang JF; Lee YC
    Mod Pathol; 2023 Jul; 36(7):100222. PubMed ID: 37336120
    [No Abstract]   [Full Text] [Related]  

  • 29. Multicenter Harmonization Study of Pan-Trk Immunohistochemistry for the Detection of NTRK3 Fusions.
    Adam J; Stang NL; Uguen A; Badoual C; Chenard MP; Lantuéjoul S; Maran-Gonzalez A; Robin YM; Rochaix P; Sabourin JC; Soubeyran I; Sturm N; Svrcek M; Vincent-Salomon A; Radosevic-Robin N; Penault-Llorca F
    Mod Pathol; 2023 Aug; 36(8):100192. PubMed ID: 37084942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NTRK fusion analysis reveals enrichment in Middle Eastern BRAF wild-type PTC.
    Kong Y; Bu R; Parvathareddy SK; Siraj AK; Siraj N; Al-Sobhi SS; Al-Dayel F; Al-Kuraya KS
    Eur J Endocrinol; 2021 Apr; 184(4):503-511. PubMed ID: 33524004
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and detection methodology for preliminary exploration of NTRK fusion in gastric cancer from a single-center retrospective cohort.
    Dong K; Yin L; Wang Y; Jia L; Diao X; Huang X; Zhou L; Lin D; Sun Y
    Hum Pathol; 2024 Jun; 148():87-92. PubMed ID: 38653403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fluorescent In Situ Hybridization Must be Preferred to pan-TRK Immunohistochemistry to Diagnose NTRK3-rearranged Gastrointestinal Stromal Tumors (GIST).
    Castillon M; Kammerer-Jacquet SF; Cariou M; Costa S; Conq G; Samaison L; Douet-Guilbert N; Marcorelles P; Doucet L; Uguen A
    Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):626-634. PubMed ID: 33758144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elaboration of NTRK-rearranged colorectal cancer: Integration of immunoreactivity pattern, cytogenetic identity, and rearrangement variant.
    Wu S; Liu Y; Shi X; Zhou W; Zeng X
    Dig Liver Dis; 2023 Dec; 55(12):1757-1764. PubMed ID: 37142453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.
    Zhang Z; Pang J; Chen L; Chen J; Li J; Liu H; Wang J; Wu H; Liang Z
    Hum Pathol; 2022 Nov; 129():21-31. PubMed ID: 35977594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.
    Vingiani A; Lorenzini D; Conca E; Volpi CC; Trupia DV; Gloghini A; Perrone F; Tamborini E; Dagrada GP; Agnelli L; Capone I; Busico A; Pruneri G
    Cancer Biomark; 2023; 38(3):301-309. PubMed ID: 37545217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Two-Step Diagnostic Approach for NTRK Gene Fusion Detection in Biliary Tract and Pancreatic Adenocarcinomas.
    Demols A; Rocq L; Perez-Casanova L; Charry M; De Nève N; Ramadhan A; Van Campenhout C; De Clercq S; Maris C; Closset J; Lucidi V; Salmon I; D'Haene N
    Oncologist; 2023 Jul; 28(7):e520-e525. PubMed ID: 36994874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
    Hung YP; Jo VY; Hornick JL
    Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive 'biomarker piggybacking': an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry.
    Sholl LM; Zheng M; Nardi V; Hornick JL
    Histopathology; 2021 Aug; 79(2):260-264. PubMed ID: 33682174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TRK Protein Expression in Merkel Cell Carcinoma Is Not Caused by
    Cappellesso R; Nicolè L; Del Fiore P; Barzon L; Sinigaglia A; Riccetti S; Franco R; Zito Marino F; Munari G; Zamuner C; Cavallin F; Sbaraglia M; Galuppini F; Bassetto F; Alaibac M; Chiarion-Sileni V; Piccin L; Benna C; Fassan M; Mocellin S; Dei Tos AP
    Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.